- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Cough Suppressant: Codeprex Now FDA-Approved
The FDA has approved codeine polistirex/chlorpheniramine polistirexextended-release suspension CIII(Codeprex), from Celltech Group,for relief of cough. This drug is thefirst codeine-based cough suppressanton the market to provide 12-hour dosing.
Twelve-Hour Extended-ReleaseCodeine Cough SuppressantThe FDA has approved codeine polistirex/chlorpheniramine polistirexextended-release suspension CIII(Codeprex), from Celltech Group,for relief of cough. This drug is thefirst codeine-based cough suppressanton the market to provide 12-hour dosing.This agent is contraindicatedin persons who are sensitive to codeineor chlorpheniramine. In addition,use with caution in patientswho have chronic cough, as occurswith smoking, asthma, or emphysema,or cough accompanied by excessivephlegm. Caution is also advisedin prescribing this drug tothose who have narrow-angle glaucomaor prostatic hypertrophy. Considerthe possibility of toleranceand/or dependence. The most commonside effects are drowsiness,confusion, dizziness, nausea, constipation,dry mouth, headache, andallergic reactions.
